Introducing MIMIX Technology
A new novel biomaterial has been created to mimic the body’s natural chemistry and thus avoid the foreign body response. MIMIX is a new consistently hydrophilic biomaterial from Access Vascular that has the potential to change how not only vascular access devices are made - but many other healthcare technologies.
CLABSI: An Ounce of Prevention
The rise of dangerous Central Line Associated Blood Stream Infections (CLABSI) should spur a review of your hospital’s vascular access program. Here are some basic strategies to diminish the risk.
The Implication of Complications
Complications from vascular access devices can prove deadly to patients and detrimental to hospital economics with reimbursement penalties tied to these complications. The good news is they can be greatly reduced with targeted tracking and common-sense measures.
Q&A with 1st HydroPICC User
The very first clinical user of HydroPICC has used it in 50 cases, with no occlusions to date. We thought it would be interesting for him to share his experience with other vascular access specialists, for whom HydroPICC could be beneficial. Many thanks to Joseph Bunch, RN, Principal Owner of Provasc, Ltd., a leading PICC placement firm in Chicagoland, Illinois, for sharing his perspective.